B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

MBD2

MOLECULAR TARGET

methyl-CpG binding domain protein 2

UniProt: Q9UBB5NCBI Gene: 893215 compounds

MBD2 (methyl-CpG binding domain protein 2) is targeted by 15 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting MBD2

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1DEAD-box RNA Helicases1.102
2Thioctic Acid1.102
3Methylene Blue1.102
4Ampicillin Semi-synthetic derivative of penicillin that functions as1.102
5Cefixime1.102
6Ethidium1.102
7Levodopa1.102
8Thioctic Acid1.102
9myricetin-3-O-galactopyranoside [Supplementary Concept]0.691
10Demeclocycline0.691
11Didanosine0.691
12Dinitolmide0.691
13Edaravone0.691
14Ribitol0.691
15Xylitol0.691

About MBD2 as a Drug Target

MBD2 (methyl-CpG binding domain protein 2) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 15 compounds with documented MBD2 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

MBD2 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.